article thumbnail

Novo Nordisk, Eli Lilly's obesity drugs will lead in new drug sales in 2024: Evaluate

Fierce Pharma

Expect more of the same in 2024, according to a report from Evaluate, which places Novo and Lilly in the top two spots for global new sales.

Sales 268
article thumbnail

Leading AstraZeneca investor defends CEO pay ahead of shareholder vote: FT

Fierce Pharma

Leading AstraZeneca investor defends CEO pay ahead of shareholder vote: FT zbecker Wed, 04/10/2024 - 10:49

Leads 146
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK’s Leading Management Consultants 2024

Curzon Consulting

29th February 2024 1 Minutes We are delighted to have been recognised again as one of the ‘UK’s Leading Management Consultants 2024’ by the Financial Times Recommended across 11 categories an increase from 8 in 2023, the annual rating, compiled with data company Statista is based on endorsements by clients and peers.

article thumbnail

JPM24: Riding label expansions and launches, AZ plots course toward 'industry-leading growth' by 2030

Fierce Pharma

With a late-stage pipeline spanning more than 120 clinical trials and a firm grasp of five major disease areas, AstraZeneca appears confident heading into 2024. | In AZ's push to reach industry-leading growth by 2030, confidence is key, chief financial officer Aradhana Sarin said at the J.P. Morgan Healthcare Conference.

Leads 253
article thumbnail

Analytica 2024 in overview

European Pharmaceutical Review

International participation and trending topics With over 900 exhibitors, analytica 2024 promises an impressive lineup. analytica 2024 provides a comprehensive overview of innovative analytics and molecular – as well as microbiological – testing methods. Top topics at the trade fair include digitalisation, Laboratory 4.0,

article thumbnail

Antibiotic demonstrates non-inferiority to a leading gonorrhoea treatment

European Pharmaceutical Review

These results for the antibiotics treatment will be presented at the 2024 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global at the end of the month. The post Antibiotic demonstrates non-inferiority to a leading gonorrhoea treatment appeared first on European Pharmaceutical Review.

Leads 95
article thumbnail

After Data Miss in Lead Cancer Indication, Replimune Maps Path for Oncolytic Virus

MedCity News

Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.

Leads 114